MEK1 inhibitors, in combination with rapid accelerated fibrosarcoma B-type (BRAF) inhibitors, have dramatically improved tumor response rate and progression-free survival in patients with stage III or IV metastatic BRAF-mutated melanoma [10]. Here, BRAF is linked to neoplasm.